Serialisation is a means to track and trace products to help overcome counterfeit drugs. Serialisation legislation is already enforced in Brazil, South Korea and China, due to come into effect in the US in 2017, and in all European countries by Feb 2019 for all prescription drugs.
With the increasing pressure to reduce inventory across the supply chain, pharmaceutical companies are increasingly using track and trace technology to create a complete overview of where their products are at any given time. As a CDMO supporting global pharmaceutical companies, Aesica have developed a serialisation module that is flexible, scaleable and able to aggregate serial numbers.
In this third webinar, Catherine Kay, Operations Director at Aesica will discuss the challenges of serialisation and how serialisation capability could be developed to address future needs. For example, if patients can only afford a limited number of tablets at any given time, serialisation to the blister pocket level may be a future requirement.
Viewers will learn about:
- Future opportunities for serialisation
- Third party logistic providers and the impact of serialisation
Catherine Kay, Operations Director, Aesica Pharmaceuticals
Catherine Kay is the Operations Director at Aesica Pharmaceuticals Limited. As part of her role, she is responsible for the coordination of the timely implementation of serialisation across all of the Aesica Packaging Sites.
Catherine has over 22 years’ experience in a variety of roles within the Pharmaceutical Industry. She gained extensive experience in production operations management and quality assurance from roles at Merck Sharp & Dohme and Eisai Manufacturing Limited before joining Aesica. Catherine holds a Masters of Chemistry degree and is a Qualified Person.Message Presenter
Who Should Attend?
Professionals in Production and Supply Chain, Outsourcing Managers, Procurement, R&D Managers
Aesica, a Consort Medical business, is a full-service partner for the development and manufacturing of active pharmaceutical ingredients (APIs) and finished dosage forms. We partner with customers to provide a flexible, efficient and dependable service that leverages our innovative approach and more than 30 years’ experience.
Our manufacturing facilities meet the highest standards according to regulatory and customer audits, allowing us to effectively manage our customers’ supply chain. We continuously invest in the latest technologies and develop our people to stay at the forefront of the industry.
As part of the Consort Medical Group, we work together with our Bespak colleagues to accelerate the route to market of drug-device combinations, through streamlined supply, for our customers at any stage of the development cycle. Across the group, we currently have 11 facilities across Europe supported by a global sales presence including North and South America, China, India, and Japan.